Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Max J. M. Silvis"'
Autor:
Mirthe Dekker, Farahnaz Waissi, Max J. M. Silvis, Joelle V. Bennekom, Arjan H. Schoneveld, Robbert J. de Winter, Ivana Isgum, Nikolas Lessmann, Birgitta K. Velthuis, Gerard Pasterkamp, Arend Mosterd, Leo Timmers, Dominique P. V. de Kleijn
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Plasma osteoprotegerin (OPG) and vascular smooth muscle cell (VSMC) derived extracellular vesicles (EVs) are important regulators in the process of vascular calcification (VC). In population studies, high levels of OPG are associated with ev
Externí odkaz:
https://doaj.org/article/9765ad5d9fff425aa1f3521772d3c650
Autor:
Max J. M. Silvis, Gerardus P. J. van Hout, Aernoud T. L. Fiolet, Mirthe Dekker, Lena Bosch, Martijn M. J. van Nieuwburg, Joyce Visser, Marlijn S. Jansen, Leo Timmers, Dominique P. V. de Kleijn
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Preclinical models that resemble the clinical setting as closely as possible are essential in translating promising therapies for the treatment of acute myocardial infarction. Closed chest pig left anterior descending coronary art
Externí odkaz:
https://doaj.org/article/48f72536db684e9796a4b598d6cc069d
Autor:
Mirthe Dekker, Farahnaz Waissi, Joelle van Bennekom, Max J. M. Silvis, Nathalie Timmerman, Ingrid E. M. Bank, Joan E. Walter, Christian Mueller, A. H. Schoneveld, Raymond M. Schiffelers, Gerard Pasterkamp, Diederick E. Grobbee, Robbert J. de Winter, A. Mosterd, Dominique P. V. de Kleijn, Leo Timmers
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Abstract Diagnosing stable ischemic heart disease (IHD) is challenging, especially in females. Currently, no blood test is available. Plasma extracellular vesicles (EV) are emerging as potential biomarker source. We therefore aimed to identify stress
Externí odkaz:
https://doaj.org/article/59575484f3ea45c389f59fdfc9efc0c8
Autor:
Max J. M. Silvis, Evelyne J. Demkes, Leo Timmers, Fatih Arslan, Saskia C. A. de Jager, Joost P. G. Sluijter, Arend Mosterd, Dominique P. V. de Kleijn, Lena Bosch, Gerardus P. J. van Hout
Publikováno v:
Biomedicines, Vol 10, Iss 12, p 3056 (2022)
NLRP3-inflammasome-mediated signaling is thought to significantly contribute to the extent of myocardial damage after myocardial infarction (MI). The purpose of this study was to investigate the effects of the NLRP3-inflammasome inhibitor IZD334 on c
Externí odkaz:
https://doaj.org/article/8797b0c53dd94455a8ff3413276c725f
Autor:
Evelyne J. Demkes, Steven Wenker, Max J. M. Silvis, Martijn M. J. van Nieuwburg, M. Joyce Visser, Marlijn S. Jansen, Maike A. D. Brans, Evelyn Velema, Joost P. G. Sluijter, Imo E. Hoefer, Dominique P. V. de Kleijn, Leo Timmers, Saskia C. A. de Jager
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Ischemia-reperfusion and cardiac remodeling is associated with cardiomyocyte death, excessive fibrosis formation, and functional decline, eventually resulting in heart failure (HF). Glucagon-like peptide (GLP)-1 agonists are reported to r
Externí odkaz:
https://doaj.org/article/d792ea9a5a5a406d8a2b3bdf94c0194c
Autor:
Max J. M. Silvis, Selma E. Kaffka genaamd Dengler, Clémence A. Odille, Mudit Mishra, Niels P. van der Kaaij, Pieter A. Doevendans, Joost P. G. Sluijter, Dominique P. V. de Kleijn, Saskia C. A. de Jager, Lena Bosch, Gerardus P. J. van Hout
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
In the setting of myocardial infarction (MI), ischemia reperfusion injury (IRI) occurs due to occlusion (ischemia) and subsequent re-establishment of blood flow (reperfusion) of a coronary artery. A similar phenomenon is observed in heart transplanta
Externí odkaz:
https://doaj.org/article/2ad6034569004103aea0b56035843858
Autor:
Amber van Broekhoven, Niekbachsh Mohammadnia, Max J. M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Willem A. Bax, Jan G. P. Tijssen, Dominique P. V. de Kleijn, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel
Publikováno v:
Clinical drug investigation, 42(11), 977-985. Adis International Ltd
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Contains fulltext : 288089.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7e75f557f8750b00f611a1192bac17
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
Autor:
Amber, van Broekhoven, Niekbachsh, Mohammadnia, Max J M, Silvis, Jonathan, Los, Aernoud T L, Fiolet, Tjerk S J, Opstal, Arend, Mosterd, John W, Eikelboom, Stefan M, Nidorf, Charley A, Budgeon, Elizabeth, Byrnes, Willem A, Bax, Jan G P, Tijssen, Dominique P V, de Kleijn, Peter L, Thompson, Saloua, El Messaoudi, Jan H, Cornel
Publikováno v:
Clinical drug investigation. 42(11)
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d07042becebf7a0c0187e7359dee4e8a
https://pubmed.ncbi.nlm.nih.gov/36208364
https://pubmed.ncbi.nlm.nih.gov/36208364
Publikováno v:
Netherlands Heart Journal
Netherlands Heart Journal, 30, 1, pp. 25-37
Netherlands Heart Journal, 30, 25-37
Netherlands Heart Journal, 30, 1, pp. 25-37
Netherlands Heart Journal, 30, 25-37
Contains fulltext : 249997.pdf (Publisher’s version ) (Open Access) Patients with coronary disease remain at high risk for future cardiovascular events, even with optimal risk factor modification, lipid-lowering drugs and antithrombotic regimens. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6549cb3cdc6b75b5597c61e282f0081
https://doi.org/10.1007/s12471-021-01605-3
https://doi.org/10.1007/s12471-021-01605-3
Autor:
Arif A Khokhar, Carlo Zivelonghi, Mirthe Dekker, Geert E. Leenders, Roberto Ferrari, F Sgura, Stefan Verheye, Giuseppe Tarantini, Alessandro Cafaro, Jan-Peter van Kuijk, Stefano Guarracini, Christoph Liebetrau, Maayan Konigstein, Sergio Berti, Dan Ioanes, Matjaž Bunc, Pieter R. Stella, Leo Timmers, Issameddine Ajmi, Antonio Colombo, Shmuel Banai, Ranil de Silva, Francesco Ponticelli, Pierfrancesco Agostoni, Claudio Rapezzi, Max J. M. Silvis, Alfonso Ielasi, Matteo Tebaldi, M. Ciardetti, Jan Sebastian Wolter, Michele Di Mauro, Kevin Cheng, Gianluca Campo, Simon Redwood, Guglielmo Gallone, Francesco Giannini, Tiffany Patterson, Federico De Marco, Gianpiero D'Amico, Steffen Schnupp, Steven Lindsay
Publikováno v:
International Journal of Cardiology. 337:29-37
Introduction Refractory angina (RA) is considered the end-stage of coronary artery disease, and often has no interventional treatment options. Coronary sinus Reducer (CSR) is a recent addition to the therapeutic arsenal, but its efficacy has only bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2028cf7a18200abd6a68e2e3714b57ee
https://doi.org/10.1016/j.ijcard.2021.05.034
https://doi.org/10.1016/j.ijcard.2021.05.034